Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin)

Semin Nucl Med. 2004 Jan;34(1 Suppl 1):10-3. doi: 10.1053/j.semnuclmed.2003.11.004.

Abstract

Yttrium 90 ibritumomab tiuxetan consists of the murine monoclonal antibody ibritumomab securely bound to the second-generation chelator tiuxetan, which attaches the high-energy pure beta emitter (90)Y, for therapy, or the gamma emitter indium 111, for imaging. The biodistribution of the therapeutic dose of (90)Y ibritumomab tiuxetan can be predicted by using an imaging dose of the antibody labeled with (111)In. Calculation of the therapeutic dose is simple and is based on patient weight and baseline platelet count: for patients with a platelet count of 150 x 10(9)/L or greater the dose of is 0.4 mCi/kg; for patients with mild thrombocytopenia (platelet count 100 x 10(9)/L to 149 x 10(9)/L) the dose is reduced to 0.3 mCi/kg; and the total dose should not exceed 32 mCi. Patients with platelet counts of less than 100 x 10(9)/L should not be treated with (90)Y ibritumomab tiuxetan. Imaging with (111)In ibritumomab tiuxetan is performed only to assess biodistribution of the radioimmunoconjugate. Uptake in sites of pathologic adenopathy, as well as other areas of lymphomatous involvement, is frequently seen on the images, but visualization of tumor uptake is not required to proceed with the therapeutic dose of (90)Y ibritumomab tiuxetan.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / therapeutic use*
  • Diagnostic Imaging*
  • Humans
  • Lymphoma, Non-Hodgkin / radiotherapy*
  • Radioimmunotherapy*
  • Radiotherapy Dosage
  • Tissue Distribution
  • Yttrium Radioisotopes / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Yttrium Radioisotopes
  • ibritumomab tiuxetan